09:59 AM EST - Medicenna Therapeutics Corp. : Announced that the United States Patent and Trademark Office issued a Notice of Allowance related to the Company's MDNA57 program. The allowed patent issued to Medicenna covers the composition of engineered interleukin-4. Superkines coupled to potent fully human cytotoxic payloads. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $1.58.
